Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 23;13:996746. doi: 10.3389/fimmu.2022.996746

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Haas, Markov, Muerner, Rubino, Benjak, Haubitz, Baerlocher, Ng, Münz, Riether, Ochsenbein, Simon and von Gunten

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Occurrence of Siglec-7⁺ CD8+ T cells glyco-immune checkpoints in AML. (A) Representative flow cytometric histogram demonstrating Siglec-7 ligands surface expression on AML cells isolated from bone marrow (BM). (B–C) Siglec-7 ligands expression on AML patient peripheral blood leukemic cells (n=6) and leukemic stem cells (LSC; n=5) (B), or bone marrow leukemic cells (n=5) and leukemic stem cell (LSC; n=4) (C). (D) RNA expression of sialyltransferases in AML patients based on TCGA Network data computed by a dendrogram clustering algorithm and (E) gene set enrichment analysis performed using hallmark gene sets (n=818). (F) Quantitative analysis of Siglec-7 expression by CD8+ T cells from the PB (PB, n=8) and from the bone marrow (BM, n=5) of patients with acute myeloid leukemia (AML). (G) Radar chart of flow-cytometric data demonstrating surface coexpression of Siglec-7 with PD1, CTLA4, BTLA, LAG3, or TIM3 on CD8+ T cells from AML bone marrow (n=4). Statistical analyses were performed by one-way ANOVA followed by Bonferroni posttest (F) ***P < 0.001; n.s., not significant. Error bars, SD.